Alterations of Dialysate Markers in Chronic Peritoneal Dialysis Patients Treated with the New Less Bioincompatible Bicarbonate Solutions

Zareie M. , Hekking L. , Welten A.G. , Driesprong B.A. , Schadee-Eestermans I.L. , Faict D. Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo. Nephrol Dial Transplant 2003; 18: 2629–37.

Rippe B. , Simonsen O. , Heimburger O. , Christensson A. , Haraldsson B. , Stelin G. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348–57.

Jones S. , holmes C.J. , Krediet R.T. , Mackenzie R. , Faict D. , Tranæus A. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529–38.

Zweers M.M. , de Waart D.R. , Smit W. , Struijk D.G. , Krediet R.T. Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J lab Clin Med 1999; 134: 124–32.

Cooker L.A. , Luneburg P. , holmes C.J. , Jones S. , Topley n ; the Bicarbonate/lactate Study Group. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 2001; 21(Suppl 3): S102–7.

Mortier S. , Faict D. , Schalkwijk C.G. , Lameire N.H. , De Vriese A.S. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66: 1257–65.

Ho-dac-Pannekeet M.M. , Hiralall J.K. , Struijk D.G. , Krediet R.T. Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int 1997; 51: 888–93.

Topley n Membrane longevity in peritoneal dialysis: impact of infection and bio-incompatible solutions. Adv Ren replace Ther 1998; 5: 179–84.

Ho-dac-Pannekeet M.M. , Krediet R.T. Inflammatory changes in vivo during CAPD: what can the effluent tell us? Kidney Int Suppl 1996; (56): S12–16.

McIntyre C.W. Update on peritoneal dialysis solutions. Kidney Int 2007; 71: 486–90.